loader from loading.io

In the News... Vertex buys Viacyte, Tandem mobile bolus begins roll out, a One Drop sensor and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

Release Date: 07/15/2022

In the News... Testing for T1D before symptoms, extended infusion sets, hysterectomy & T2D and more! show art In the News... Testing for T1D before symptoms, extended infusion sets, hysterectomy & T2D and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It's "In the News..." a look at the top diabetes stories and headlines of the past seven days. This week: new information about COVID and type 1 in kids, a new way to look for diabetes before symptoms appear, Medtronic may be ready to ship their 7-day infusion set, approved more than a year ago, and more. Thanks to our sponsor, T1D Exchange: www.t1dexchange.org/Stacey Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top...

info_outline
Guest interview: Guest interview: "Nerdabetic" talks to Dexcom's Jake Leach

Diabetes Connections with Stacey Simms Type 1 Diabetes

Dexcom's G7 is still not approved in the United States, but it's in limited release in Europe. This week, friend of the show Kamil Armacki, better known as Nerdabetic, interviews Dexcom's Chief Operating Officer, Jake Leach. Find more about Kamil over at his amazing YouTube Channel here: https://www.youtube.com/c/nerdabetic This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible!

info_outline
In the News.. Medtronic safety alert, Omnipod 5 in Europe, T1D Index launched and more! show art In the News.. Medtronic safety alert, Omnipod 5 in Europe, T1D Index launched and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It’s In the News! This week’s top diabetes headlines and stories include: cybersecurity risk cited for some Medtronic pumps, Omnipod 5 gets European approval, new data about the Freestyle Libre and avoiding hospitalizations, the new T1D Index and more! Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange...

info_outline
"I think it's just the beginning" - A new way to test DIY pump systems from UVA

Diabetes Connections with Stacey Simms Type 1 Diabetes

Researchers at UVA recently published a study called Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems. They say what they’ve set up here is quote - a valid tool that can be used by the research community to demonstrate the effectiveness of different control algorithms and safety features for APS, automated pancreas systems. This week, you'll hear from Xugui Zho and Homa Alemzadeh, two of the researchers on this study. Link to the study: This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health...

info_outline
In the News.... Screening kids for diabetes, New shot for T2D, 92 years old with T1D and more! show art In the News.... Screening kids for diabetes, New shot for T2D, 92 years old with T1D and more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It's In the News! This week's top diabetes headlines and stories include: with more cases of type 1 and type 2 diabetes in US kids, researchers look into whether more screenings should take place. There's a new injectable on the market that some studies show can reduce the risk of type 2 diabetes in overweight and obese people, Medtronic faces a shareholder lawsuit and a 92-yar old Long Island woman, diagnosed as a child, may be one of the oldest living people with type 1. She has some great things to say about what helps her manage well all this time! Episode Transcription Below (or coming...

info_outline
25 Marathons, One World Series of Poker, and 23 Years of T1D: Meet Doug Scalia show art 25 Marathons, One World Series of Poker, and 23 Years of T1D: Meet Doug Scalia

Diabetes Connections with Stacey Simms Type 1 Diabetes

Doug Scalia has completed 25 marathons in 15 states. He’s about to add three more to his list, including the . He knows it sounds like an impossible feat for many, but he says anyone can do it! Doug was diagnosed as a young adult and he’s also played in the World Series of Poker so we have a lot to talk about. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible!

info_outline
In the News.. Islet cell implant update, BG check with radio waves, preschool T1D detection & more! show art In the News.. Islet cell implant update, BG check with radio waves, preschool T1D detection & more!

Diabetes Connections with Stacey Simms Type 1 Diabetes

It’s in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more! Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes Connections In the News! I’m Stacey...

info_outline
Omnipod 5: Answering your questions about Omnipod 5: Answering your questions about "real world" use

Diabetes Connections with Stacey Simms Type 1 Diabetes

Omnipod 5 was approved earlier this year and just rolled out to a wider release. So how is the first tubeless automated insulin delivery system doing in the real world? We put together a panel of early adopters and got their feedback. That was great, but it brought up quite a few questions, so we reached out to Omnipod for clarification and follow up. The result is a super-sized episode full of info! Our panel: Liat Kochavi, mother an almost-8-year-old with T1D, Stephanie Williams, mother of a teen with type 1, and Sam Durante who was diagnosed with type 1 just before she turned 16. You'll...

info_outline
In the News, Oral insulin for T1D moves forward, T2D drug helps hearts, type 1 and teen brains and more show art In the News, Oral insulin for T1D moves forward, T2D drug helps hearts, type 1 and teen brains and more

Diabetes Connections with Stacey Simms Type 1 Diabetes

It’s in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more! Learn about the T1d Exchange: ----- available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms...

info_outline
"How was eight weeks away at camp?" An interview with 17-year-old Benny

Diabetes Connections with Stacey Simms Type 1 Diabetes

Stacey's son spent the summer away at regular, non-diabetes sleepaway camp. 8 weeks managing all of his own care, with no remote monitoring. You had a lot of questions, including how he manages overnight lows: Benny is 17, he was diagnosed just before he turned two and, as usual, he has a lot to say. He had quite a few adventures at camp, but everything turned out okay. We get his take on independence, responsibility and a glimpse into how a teen with type 1 thinks. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. ...

info_outline
 
More Episodes

Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem's new mobile bolus feature, One Drop shows a "health sensor" on its website, a study shows that screening for type 1 at very young ages could help detect most cases and much more!

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Our top story this week, Vertex buys Viacyte! For context, Vertex is the company that got all the headlines last fall – big article in the New York Times for a stem cell therapy that brought one person with type 1 off insulin completely. The FDA put them on hold but lifted that just last week. Vertex previously acquired Dr. Doug Melton's Semma.
Viactye is the company featured in the documentary "The Human Trial" - they're using CRISPR technology to keep the body from rejecting their stem cells. Both companies technology does NOT require immunosuppressive drugs and both say they are working toward a functional cure. Some experts are saying this will speed up that effort while critics worry that it eliminates the competitive aspect of the race. Sernova is still one separate company that has shown stem cell therapy can work.. I’ve got requests out to Viacyte to talk to us about all of this, so stay tuned.
https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-viacyte-goal-accelerating-its-potentially?fbclid=IwAR15qlFSBsBR89blzXymyIGL3tW5C64QtdHpwq7a5fdjmv2q6JmfoTIpm-k
XX
If we widely screened kids for type 1 at certain ages, a new study suggests, it would identify most of those who go on to develop it by their teen years. These researchers looked at screening for the type 1 autoantibodies at ages 2 and 6. This included nearly 25-thousand children from Europe and US. One issue in this study, funded by JDRF, all the participants in the combined dataset had genetic risk factors for the disease or a relative with type 1 diabetes, in whom performance is expected to be higher. It also included almost exclusively kids of northern European ancestry.
https://www.medscape.com/viewarticle/976992
XX
Tandem bolus by phone is slowly rolling out. This week, the T:Connect app was updated in the The t:connect app was updated and emails started arriving for those notified they were part of the early release groups. I did see some reports of people not yet getting the email but seeing the update in their portal so be sure and check. Mobile Bolus is reportedly available for those using Control IQ and Basal IQ. It’s worth noting that for those outside the US there really is no timeline, but Tandem has previously said they’re going to replace t:connect with a new system that will debut outside the US first. By the way, I got my email this morning, but Benny is still at camp for three more weeks so it'll be a bit before we do the update!
XX
Interesting look at teens and young adults with type 1.. the early morning psychosocial state may explain a proportion of their daily variance in time in range. The study included 88 participants aged between 14 and 26 years, 56-percent of whom were women. This is tough to quantify but they had the participants complete an engagement prediction survey and set a diabetes management goal for the day when they woke up, and also completed an evening survey. These questions were about mood, motivation, control beliefs, social support, stress, general health, self-esteem, and perceived need for assistance.

Of note, lower morning glucose levels correlated with measures of good sleep, high motivation, and good health, whereas higher morning glucose levels were associated with illness and feeling the need for support.
https://www.medwirenews.com/diabetes/morning-mindset-daily-glucose-fluctuations-young-people-diabetes/23255450
XX
Good catch by our friend Nerdabetic over on Twitter.. One Drop plans to enter what they’re calling the continuous health sensing market with a daily disposable, minimally invasive biosensor in development. They say this is designed to provide greater flexibility and insights for people living with diabetes compared to blood glucose monitor (BGM) fingersticks alone. The availability of our continuous health sensor is subject to receipt of clearance or approval from the U.S. Food and Drug Administration. Pending regulatory approval and commercial adoption, we believe integrating the One Drop health sensor with our existing digital solution, One Drop Premium, should augment proven outcomes and yearly cost savings for members living with diabetes and other chronic conditions.
https://onedrop.today/blogs/blog/bgm-vs-cgm?utm_source=twitter&utm_medium=social-organic&utm_campaign=social-campaign_jul-2022&utm_content=blog
XX
Navitus Health Solutions, which is owned by Costco & SSM Health – has joined CivicaScript as a founding member. CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market. Earlier this year they announced they would be adding insulin to that list, but it likely won’t be available for at least two years. This partnership would seem to insure the lower cost insulin will be available at Costco pharmacies, which you don’t have to have a membership to use.

https://www.businesswire.com/news/home/20220713005349/en/Navitus-Health-Solutions-Joins-CivicaScriptTM-to-Further-Availability-of-Lower-Cost-Generic-Medications/?fbclid=IwAR0vBF0YlCo9ZJ-9Yd0nLag_Mjuf8s4YpnR9IJVudvVGDR1Rj508HSd_kXw
XX
Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It’s a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that’s S-T-A-C-E-Y).
XX
The Food and Drug Administration received more than a thousand comments—mainly from diabetes patients and their family members—in response to draft cybersecurity guidance. These are for staff to use when processing submissions from medical-device manufacturers.

“Please do not let medical device manufacturers use cybersecurity as a pretense to prevent me from accessing my OWN devices,” reads one entry from a sample of the comments FDA posted to the docket on the guidance.

Howard Look, CEO of Tidepool is quoted in some of the article around this. Tidepool provides software that allows patients to see their data and better manage the disease. And supporters are working to make Tidepool Loop the first FDA approved app for more convenient automated insulin delivery.
“Following best practices for cybersecurity does not need to imply blocking patient users from accessing their own data or controlling their own devices,” the comments read. “Tidepool asserts there is a risk that the FDA guidance will be interpreted or misinterpreted to suggest restriction of access by the patient user is appropriate or encouraged. The FDA can mitigate this risk by clearly stating a patient user’s access to and use of their own device can be considered authorized access, and should not be considered a cybersecurity threat.”
With a 90-day public comment period ending Thursday, the FDA will now begin the process of finalizing cybersecurity guidance for its pre-market submissions, according to a notice in the Federal Register.

https://www.nextgov.com/cybersecurity/2022/07/diabetes-patients-flood-fda-comments-cybersecurity-medical-devices/374020/
XX

Congrats to the team over at Divabetic Podcast – which celebrates 12 years this month! Divabetic was inspired by the late R&B legend, Luther Vandross, and founded in 2005 by his long-time assistant, Max “Mr. Divabetic” Szadek. It’s now a national nonprofit organization that uses highly engaged, non-traditional virtual programs, videos and podcasts to promote prevention, early action and education. Congrats to Max and the entire team!
https://divabetic.org/about-us/
XX
Next week you’ll hear from the folks at Diabetes Wise – that’s a website to help you choose diabetes technology.. they’ve added information for doctors – this may help you educate your heathcare providers on why you want the pump or cgm system that you do.. the long format episode out right now is all about campviews, a new system that lets diabetes camps see every camper’s CGM all at once.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.